$Unity Biotechnology(UBX)$One of the reasons for the rise in healthcare spending comes down to longevity. Aging and staying alive longer creates a lot of problems for people. The forefront of this could be newly IPO’d Unity Biotechnology Inc (NASDAQ:UBX).
Unity is a very early stage clinical biotech — the opposite of previously mentionedMorphoSys.But its approach seems worthy of a portfolio position. UBX is developing so-called senolytic therapies to treat age-related diseases. These medicines selectively induce the death of senescent cells. Senescent cells are those that have stop dividing. For age-related disorders, this is fertile ground for treatment. By blocking these cells, Unity hopes to halt various age-related diseases.
Comments